Navigation Links
Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Date:3/22/2010

NANJING, China, March 22 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study. The New Drug Research Institute of Cancer Hospital, the Chinese Academy of Medical Science and the Chinese Society of Clinical Oncology (CSCO) hosted the event.

Endostar is approved as a Class-1 drug by the State Food and Drug Administration (SFDA) for the treatment of cancer (license no. S20050074). Since September 2005, the Chinese government has licensed Endostar to treat Non-Small-Cell Lung Cancer (NSCLC). Endostar is a modified version of recombinant human Endostatin designed to stop the growth of cancer by starving it of oxygen and other nutrients. It is the first anti-angiogenic drug successfully launched in the world and is regarded among the healthcare community as a key milestone in the development of anti-cancer treatment. Endostar is recommended in the National Comprehensive Cancer Network of China Clinical Practice Guidelines in Oncology Chinese (Version 2006-2008) as a first line treatment for NSCLC.

Following changes in the Provisions for Drug Registration in China in 2005, Simcere invited Prof. Sun Yan from the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences as Principal investigator, and the other 153 famous medical centers, to conduct a Phase IV clinical study for Endostar to further evaluate the safety and efficacy of this innovative new drug. The study was designed as an open label, prospective, and multi-center study and was the first Phase IV clinical study for a Class-1 new drug in China.

Endostar Phase IV clinical study passed the IRB/EC committee board of the Chinese Academy of Medical Science on November 10, 2006 and has taken two and half years to complete. Enrolment of the first patients commenced December 20, 2006, and the last patient was enrolled on June 10, 2009. In total, 2725 subjects were enrolled, which is the largest clinical study ever conducted in China. The survival analysis for stage statistics showed that Mean Survival Time (MST) was 17.57 months, 1-year survival rate was 63.68%, 2-year survival rate was 39.79%, and median Time to Tumor Progression (TTP) was 7.37 months. Objective Response Rate (ORR) was 23.93%, and Disease Control Rate (DCR) was 76.07%.

The findings of Endostar Phase IV clinical study verified that Endostar Phase III and IV are comparable and by combining Endostar with standard chemotherapy regimens, this could improve the median survival time and overall survival rate of patients with advanced NSCLC with no significant increase of the adverse effects of chemotherapy.

At the conference, some investigators (such as medical centers in Sichuan and Zhejiang) reported that Endostar was found also significantly effective for the treatment of pleural/ascetic fluid and Gliomas (a type of brain tumor). Currently, there are many on-going clinical studies of Endostar including lung cancer and non-lung cancer (e.g.: Osteosarcoma and Colorectal cancer). Most of them have registered in the http://clinicaltrials.gov , the registry of US National Institutes of Health.

With the successful completion of Endostar's Phase IV clinical study, as required by the new national drug registration law, Endostar is expected to be the first new drug to successfully pass re-registration.

Professor Sun Yan, Member of the Chinese Academy of Engineering, commented at today's conference: "This Phase IV clinical study is the first of its kind to be completed in China and houses a huge amount of data which we can tap into to help patients suffering from advanced stages of Non-Small-Cell Lung Cancer. These are very encouraging results and with its re-registration, Endostar will bring relief to patients across China for many years to come."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endostar. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

SOURCE Simcere Pharmaceutical Group

Back to top

RELATED LINKS
http://www.simcere.com
http://clinicaltrials.gov

'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
2. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
3. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
6. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News
9. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
10. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
11. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... Demand Forecast to 2022" report to their offering. ... The global wound care market was worth ... CAGR of 6.7% during 2016-2022 Among the various wound care ... in the global market in 2015. Among the various applications, surgical wound ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... ... 24, 2017 , ... In just two days, Aqua Design ... garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the original ... (and counting) already backing the campaign. , “We are very grateful for ...
(Date:3/24/2017)... ... 2017 , ... Northridge dentists, Dr. Michel Elyson ... apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has long ... is increasingly being treated at dental offices with newly developed procedures and appliances. ...
(Date:3/24/2017)... ... 24, 2017 , ... The law firm of Enea, Scanlan & Sirignano, ... Westchester resident Lauren C. Enea has joined the firm as an associate attorney. Ms. ... practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... Miami, FL (PRWEB) , ... March 24, 2017 ... ... HyGIeaCare Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy ... Health Endoscopy Centers in 87th Ave., Miami, FL. , The ...
Breaking Medicine News(10 mins):